Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa

International Journal of Antimicrobial Agents

Volumn 49, Issue 2, 2017, Pages 266-268

  Xipell, Marc ^a   Bodro, Marta ^a   Marco, Francesc ^a   Losno, Ricardo A ^a   Cardozo, Celia ^a   Soriano, Alex ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; AVIBACTAM PLUS CEFTAZIDIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TOBRAMYCIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BLOOD CULTURE; BRAIN ABSCESS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESCHERICHIA COLI; EXTENSIVELY DRUG RESISTANT PSEUDOMONAS AERUGINOSA; FEMALE; HUMAN; KIDNEY ALLOGRAFT REJECTION; LETTER; LUNG ABSCESS; MALE; PSEUDOMONAS AERUGINOSA; X-RAY COMPUTED TOMOGRAPHY; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DRUG EFFECTS; MENINGITIS; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PROCEDURES; PSEUDOMONAS INFECTIONS; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG ABSCESS; MALE; MENINGITIS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85009170434     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.11.005     Document Type: Letter

References (7)

1. [1] Peña, C., Cabot, G., Gómez-Zorrilla, S., Zamorano, L., Ocampo-Sosa, A., Murillas, J., et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 60 (2015), 539–548.
2. [2] Morata, L., Cobos-Trigueros, N., Martínez, J.A., Soriano, A., Almela, M., Marco, F., et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 56 (2012), 4833–4837.
3. [3] Nichols, W.W., de Jonge, B.L., Kazmierczak, K.M., Karlowsky, J.A., Sahm, D.F., In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime–avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60 (2016), 4743–4749.
4. [4] Carmeli, Y., Armstrong, J., Laud, P.J., Newell, P., Stone, G., Wardman, A., et al. Ceftazidime–avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16 (2016), 661–673.
5. [5] Housman, S.T., Crandon, J.L., Nichols, W.W., Nicolau, D.P., Efficacies of ceftazidime–avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother 58 (2014), 1365–1371.
6. [6] European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. Basel, Switzerland. EUCAST; Available from http://www.eucast.org/clinical_breakpoints/, 2016 [Accessed 30 November 2016].
7. [7] Pitart, C., Marco, F., Keating, T.A., Nichols, W.W., Vila, J., Activity of ceftazidime–avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 59 (2015), 3059–3065.